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Objective: Living lobar lung transplantation was developed as a procedure for
patients considered too ill to await cadaveric transplantation.
Methods: One hundred twenty-eight living lobar lung transplantations were per-
formed in 123 patients between 1993 and 2003. Eighty-four patients were adults
(age, 27  7.7 years), and 39 were pediatric patients (age, 13.9  2.9 years).
Results: The primary indication for transplantation was cystic fibrosis (84%). At the
time of transplantation, 67.5% of patients were hospitalized, and 17.9% were
intubated. One-, 3-, and 5-year actuarial survival among living lobar recipients was
70%, 54%, and 45%, respectively. There was no difference in actuarial survival
between adult and pediatric living lobar recipients (P  .65). There were 63 deaths
among living lobar recipients, with infection being the predominant cause (53.4%),
followed by obliterative bronchiolitis (12.7%) and primary graft dysfunction
(7.9%). The overall incidence of acute rejection was 0.8 episodes per patient.
Seventy-eight percent of rejection episodes were unilateral. Age, sex, indication,
donor relationship, preoperative hospitalization status, use of preoperative steroids,
and HLA-A, HLA-B, and HLA-DR typing did not influence survival. However,
patients on ventilators preoperatively had significantly worse outcomes (odds ratio,
3.06, P .03; Kaplan-Meier P .002), and those undergoing retransplantation had
an increased risk of death (odds ratio, 2.50).
Conclusion: These results support the continued use of living lobar lung transplan-
tation in patients deemed unable to await a cadaveric transplantation. We consider
patients undergoing retransplantations and intubated patients to be at significantly
high risk because of the poor outcomes in these populations.
Living lobar lung transplantation was introduced in 1993 in responseto the mismatch between supply and demand for those individualsawaiting lung transplantation. The number of available cadavericorgans has remained relatively stable since 1993, despite the liber-alization of the standard donor criteria and the use of older andpotentially more marginal donors.1-3 These trends have led to a
leveling off of the annual lung transplantation rate, a doubling of the median waiting
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time, and an increase in the number of candidates who die
while awaiting transplantation.2
With living lobar lung transplantation, right and left
lower lobes from 2 healthy donors are implanted in the
recipient in place of whole right and left lungs, respectively.
Initial and intermediate survival, as well as functional out-
comes, have been previously reported, with acceptable re-
sults.1,4-11 The purpose of this study is to expand on our
series by providing an analysis of recipient outcomes during
our first decade of experience with this procedure.
Methods
Study Subjects and Design
Between January 1993 and December 2002, inclusive, 128 living
lobar lung transplantations were performed in 123 patients at the
University of Southern California University Hospital and Childrens
Hospital Los Angeles. Eighty-four patients were adults (18 years of
age), and 39 were pediatric patients (18 years of age). These patients
constitute the cohort of patients for this outcomes analysis.
Living Lobar Lung Transplantation
All lobar recipients fulfilled the criteria for cadaveric lung trans-
plantation and were listed with the United Network for Organ
Sharing. Living lobar lung transplant recipients were selected on
the basis of a deterioration of their clinical status with the expec-
tation that a cadaveric donor would not become available or that
further deterioration would make them unsuitable candidates for
cadaveric transplantation.
The process of living-donor selection and the techniques of
right and left donor lobectomy have been described previous-
ly.1,4,5,7,8,11,12 All lobar lung transplant procedures were per-
formed through a transverse thoracosternotomy with the use of
cardiopulmonary bypass and using a running polypropylene suture
for the bronchial anastomosis. All patients received triple immu-
nosuppressive therapy consisting of cyclosporine (INN: ciclos-
porin) or tacrolimus, azathioprine or mycophenolate mofetil, and
prednisone, without the use of prophylactic monoclonal or poly-
clonal antibodies.7,11 All patients received standardized prophy-
laxis against Candida species, Pneumocystis carinii, and cytomeg-
alovirus (CMV).11 In addition, those patients with cystic fibrosis
received antibiotic regimens on the basis of the results of periop-
erative cultures. Unique aspects of the perioperative management
of the bilateral lobar recipient related to the lobar physiology, as
well as donor management, have been previously described.11
Definition of Variables
Causes of death are reported on the basis of clinical findings,
autopsy findings, or both. Flexible bronchoscopy and transbron-
chial biopsies were performed when clinically indicated and with-
out the use of a routine surveillance protocol. Acute cellular
rejection was determined by means of transbronchial biopsy and
graded according to the classification of the International Society
for Heart and Lung Transplantation (ISHLT).13 Bronchiolitis ob-
literans syndrome (BOS) was defined according to standard spi-
rometric criteria.14 All patients, local or long distance, had formal
pulmonary function tests (PFTs) performed with each clinic visit.
Complete PFTs were performed at either our institution or the
referring institution at 6 months, 1 year, and at least every year
thereafter after transplantation. Results of PFTs from outside in-
stitutions were forwarded to our institution after each visit. Fol-
low-up spirometry is complete in 100% of recipients. The recipi-
ent’s functional status was graded as full (ability to work or attend
school full-time), limited (part-time school or work), severely
limited (needing chronic supplemental oxygen), or debilitated
(wheelchair or bed bound).
Statistical Analysis
Data are presented as means SD. Actuarial estimates of survival
and freedom from obliterative bronchiolitis (OB) and BOS were
derived by using life-table methods. For these analyses, Kaplan-
Meier curves were compared with results of the log-rank (Mantel-
Haenszel) test. Dichotomous variables for the following groups
were compared to evaluate the risk of postoperative death by using
a 2-tailed Fisher exact test and 95% confidence intervals: male or
female, adult or pediatric, indications for transplantation, preoper-
ative ventilation, steroid use, and hospitalization status, as well as
the presence or absence of rejection episodes and the relationship
of the donor to the recipient. For all statistical analysis, GraphPad
version 3.03 for Windows (GraphPad Software, Inc, San Diego,
Calif) or SPSS for Windows (Release 9.0.1, SPSS, Inc) were used.
Results
Demographics
Demographics, indications for transplantation, and preoper-
ative characteristics are presented for the overall cohort of
lobar lung transplant recipients, as well as for adult and pedi-
atric subgroups, in Table 1. The mean age of the overall cohort
was 23.1  9.1 years. Cystic fibrosis was the indication for
transplantation in 84.4% of recipients. Other indications in-
cluded pulmonary hypertension, idiopathic pulmonary fibrosis,
bronchopulmonary dysplasia, and OB. In addition, 2 patients
received lobar lung transplants for OB after bilateral cadaveric
transplantation. Five lobar recipients received a second lobar
transplant, 3 for primary graft failure and 2 for OB. Of lobar
recipients, 67.5% were hospitalized, and 17.9% were intubated
at the time of lobar transplantation.
Overall Survival
Overall follow-up is 374 patient-years (range, 0-9.8 years;
mean, 3.0 2.8 years). Sixty-three (51.2%) deaths occurred
during the follow-up period, 45 in adults and 18 in pediatric
recipients. As shown in Figure 1, actuarial survival in the
living lobar lung transplant recipients at 1, 3, and 5 years
was 70%, 54%, and 45%, respectively. There was no dif-
ference in actuarial survival between adult or pediatric
recipients of living lobar lung transplants (log-rank P 
.65), as shown in Figure 2.
Causes of Death
Causes of death are listed in Table 2. Fifteen deaths oc-
curred within 30 days of transplantation, with infection and
primary graft failure being the most common causes. Twen-
Starnes et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 1 115
G
TS
ty-two deaths occurred between 30 days and 1 year after
transplantation, with infectious causes being the most com-
mon. Late death (1 year after transplantation) occurred in 26
patients, with infection and OB being the predominant causes.
For the overall cohort, infection was the predominant
cause of death (52.4%), with sepsis and pneumonia from
Pseudomonas species, Staphylococcus species, and As-
pergillus species being the most common causes. Death
caused by CMV occurred in 3 patients. OB resulting in
death occurred in 8 (12.7%) recipients; the mean time to
death in these patients was 4.1  2.1 years. In addition, 2
lobar recipients underwent retransplantation for OB with 2
additional lobes at 2 and 4 years after the original trans-
plantation; one patient died 2 months after retransplantation
(because of CMV), and the other is alive 1 year after
retransplantation. Primary graft dysfunction as a cause of
death occurred in 5 patients at a mean of 25  26 days after
transplantation. Three additional patients had significant
primary graft dysfunction postoperatively and received an
additional lobe at 1, 1, and 6 weeks after the original
transplantation. Of these patients, 2 died (one because of
CMV and one because of Aspergillus species infection), and
1 is alive 7 years after retransplantation. Both patients who
received lobar transplants for OB after cadaveric lung trans-








No. of patients 123 84 39
Age (y  SD) 23.1 9.1 27.4 7.7 13.9 2.9
Female sex (%) 72 (58.5) 53 (64.3) 19 (46.2)
Number of transplantations (or number undergoing
retransplantation)
128 (5) 87 (3) 41 (2)
Recipient weight (kg  SD) – 49.9 8.9 35.2 8.9
Recipient height (cm  SD) – 163 8.6 148 15
Indication for transplantation
Cystic fibrosis (%) 108 (84.4) 76 (87.4) 32 (78.1)
Pulmonary hypertension (%) 5 (3.9) 0 (0) 5 (12.2)
Idiopathic pulmonary fibrosis (%) 5 (3.9) 5 (5.7) 0 (0)
Bronchopulmonary dysplasia (%) 1 (0.8) 1 (1.1) 0 (0)
Obliterative bronchiolitis (%) 2 (1.6) 0 (0) 2 (4.9)
Obliterative bronchiolitis after cadaveric transplantation 2 (1.6) 2 (2.3) 0 (0)
Primary graft failure after lobar transplantation 3 (2.3) 2 (2.3) 1 (2.4)
Obliterative bronchiolitis after lobar transplantation 2 (1.5) 1 (1.2) 1 (2.4)
Preoperative characteristics
Hospitalized at time of transplantation (%) 83 (67.5) 63 (75.0) 20 (51.3)
Ventilator dependent at time of transplantation (%) 22 (17.9) 17 (20.2) 5 (12.8)
Figure 1. Actuarial survival and number of patients at risk for the total cohort of living lobar lung transplant
recipients.
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plantation died, one 35 days after lobar transplantation
because of Aspergillus species infection, and the other 3
years after retransplantation from OB. Of the 5 pediatric
patients undergoing transplantation for pulmonary hyper-
tension, 4 are alive 2, 6.5, 7, and 8 years after transplanta-
tion, whereas 1 died 3.8 years after transplantation because
of OB. Two of the 5 patients undergoing transplantation for
pulmonary fibrosis are alive 1.8 and 8.6 years after trans-
plantation, whereas 3 died 27, 45, and 70 days after trans-
plantation from Aspergillus species infection, idiopathic
thrombocytopenic purpura, and bacterial pneumonia, re-
spectively. The patient with bronchopulmonary dysplasia
died 6 years after transplantation from OB. The cause of
death in patients with cystic fibrosis was predominantly
infectious (28/52 deaths), with the remaining deaths result-
ing from the causes listed in Table 2. Other less common
causes of death included liver failure, gastrointestinal bleed-
ing, idiopathic thrombocytopenic purpura, bronchiectasis,
anoxic brain injury, renal failure, diffuse alveolar disease,
and one unknown cause. Noncompliance contributed to the
death of at least 8 of these patients (12.7% of all deaths),
and chronic malnutrition and weakness resulting in pneu-
monia, multisystem organ failure, and ultimately death oc-
curred in 2 recipients.
Rejection Episodes
The overall incidence of rejection was 0.8 episodes per
patient. Of the 100 episodes of rejection seen in the 67
patients, 72% were unilateral, and 28% were bilateral. Fifty-
three percent of rejection episodes were classified as grade
A2 according to the ISHLT grading system, whereas 35%
were classified as grade A1, and 12% were classified as
grade A3. Twenty-two (33%) of the 67 recipients with
rejection had multiple episodes, and 59% of these multiple
rejection episodes occurred in the same side distribution as
with the initial rejection episode.
Freedom From OB and BOS
OB was pathologically confirmed in 17 (13.8%) patients (9
adult and 8 pediatric patients). Two patients underwent
another bilateral lobar lung transplantation, whereas 8 died
of disease. Three additional adult patients are considered to
have BOS on the basis of decreases in spirometric values,
yielding an overall incidence of 16.3% in this cohort. Over-
all freedom from BOS and OB in adult recipients is 98%,
82%, and 76% at 1, 3, and 5 years, respectively.
TABLE 2. Causes of death in living lobar lung transplant
recipients by time after transplantation









Infection (%) 33 (52.4) 5 (33.3) 16 (72.8) 12 (46.2)
Bacterial sepsis 9 (27.3) 1 (20.0) 3 (18.8) 5 (41.7)
Aspergillus species 8 (24.2) 4 (80.0) 4 (25.0) 0 (0)
Pneumonia: other 7 (21.2) 0 (0) 6 (37.5) 1 (8.3)
Pseudomonas species 4 (12.1) 0 (0) 1 (6.3) 3 (25.0)
Cytomegalovirus 3 (9.1) 0 (0) 1 (6.3) 2 (16.7)
Fungal sepsis 1 (3.0) 0 (0) 1 (6.3) 0 (0)
EBV pneumonitis 1 (3.0) 0 (0) 0 (0) 1 (8.3)
Obliterative bronchiolitis
(%)
8 (12.7) 0 (0) 0 (0) 8 (30.8)
1° Graft dysfunction (%) 5 (7.9) 4 (26.7) 1 (4.5) 0 (0)
Emboli/thrombi (%) 4 (6.3) 2 (13.3) 1 (4.5) 1 (3.8)
Cerebral edema (%) 3 (4.8) 3 (20.0) 0 (0) 0 (0)
Malnutrition (%) 2 (3.2) 0 (0) 1 (4.5) 1 (3.8)
Others (%)* 8 (12.7) 1 (6.7) 3 (13.7) 4 (15.4)
Overall no. of deaths (%) 63 15 (23.8) 22 (34.9) 26 (41.3)
EBV, Epstein-Barr virus.
*Other causes of death included liver failure, gastrointestinal bleeding,
idiopathic thombocytopenic purpura, bronchiectasis, anoxic brain injury,
renal failure, diffuse alveolar damage, and an unknown cause.
Figure 2. Actuarial survival and number of patients at risk for adult (>18 years of age) and pediatric (<18 years
of age) living lobar lung transplant recipients (log-rank P  .65).
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HLA-A, HLA-B, and HLA-DR haplotypes for the recipi-
ents and the respective donor lobes were analyzed to deter-
mine whether there was a relationship between the number
of HLA mismatches and survival. Because of the unusual
aspect of this procedure involving 2 different donors for
each recipient, the total number of mismatches could equal
12, as opposed to 6 in living-donor kidney transplantation,
which involves only one donor. When the numbers of
HLA-A, HLA-B, and HLA-DR mismatches between the
recipient and the 2 donor lobes were categorized into those
with 0, 1 to 2, and 3 to 4 total mismatches, there was no
influence on survival (data not shown). The total number of
HLA-A, HLA-B, and HLA-DR mismatches between the
recipient and donor lobes was also categorized into those
recipients with 0 to 4, 5 to 8, and 9 to 12 total mismatches;
there was no association with survival (Figure 3).
Predictors of Death
Fisher exact tests were performed to identify patient vari-
ables that might predict increased mortality. As shown in
Table 3, the odds ratios were not significant for recipient
age, sex, cystic fibrosis as an indication for transplantation,
a diagnosis other than cystic fibrosis as an indication for
transplantation, preoperative hospitalization status, preoper-
ative steroid use, presence or absence of rejection episodes,
or relationship of donor to recipient. The odds ratio for risk
of death was greater than 2.5 when comparing those recip-
ients undergoing lobar lung transplantation who were intu-
bated preoperatively and for those undergoing retransplan-
tation. Actuarial survival curves were generated to further
examine the effect of preoperative intubation on survival,
and recipients intubated preoperatively were found to have
significantly worse outcomes than those patients not intu-
bated (P  .002, Figure 4). The time to 50% survival for
intubated recipients was 0.44 years versus 4.91 years in
nonintubated recipients. Of the 16 intubated patients who
died, 9 (56%) died of infection, with Aspergillus species
being the predominant organism responsible for death in
this subgroup (78%). In addition, 7 of the 9 deaths caused
by Aspergillus species infection in the overall cohort of
lobar recipients occurred in patients intubated preopera-
tively. Actuarial survival curves comparing primary trans-
plantations with retransplantations are shown in Figure 5.
Functional Status
At the present time, all 60 current survivors (39 adult and 21
pediatric patients) are either working or attending school
full time, without any functional limitations. Three female
recipients went through full-term pregnancy without any
untoward events during gestation or delivery.
Discussion
The field of clinical lung transplantation has improved
markedly over the past 3 decades as a result of advances in
the areas of surgical technique, organ preservation, immu-
nosuppressive drug therapy, and the prevention and treat-
ment of infection. However, although the number of pa-
tients with end-stage lung disease placed on the waiting list
has increased, the availability of cadaveric donor lungs has
failed to increase to the same degree.2 In 1993, bilateral
living-donor lobar lung transplantation was introduced by
our group in response to the cadaveric lung donor shortage.1
In 1996, we reported our intermediate results with this
procedure in a cohort of 27 adult and 10 pediatric recipi-
ents.4 Average follow-up at that time was 14 months, and
1-year actuarial survival was 68%. The lobar recipients
were an extremely ill cohort of patients, primarily with
cystic fibrosis, with 22 of the 37 transplantations being
performed on an emergency basis within 72 hours of arrival
at our institution. Infection was the predominant cause of
death. In addition, pulmonary hemodynamics were accept-
able in a subcohort study of these patients. From this anal-
ysis, it became clear that living lobar transplantation was a
workable option for patients whose condition was deterio-
rating or acquiring characteristics that would make them
unsuitable candidates for cadaveric lung transplantation.
We now present an analysis of recipient outcomes for the
123 patients who have undergone this procedure at our
institution in the last decade.
Cystic fibrosis remains the predominant indication for
transplantation in these recipients. The high percentage of
patients with cystic fibrosis undergoing transplantation in
our experience reflects referral patterns, donor-to-recipient
size-matching requirements, and psychosocial dynamics
within this group of patients. As with our previous reports,
this patient population continues to be a sick cohort, with
75% of adult and 51% of pediatric patients being hospital
Figure 3. Actuarial survival according to the total number of
HLA-A, HLA-B, and HLA-DR mismatches between the recipient
and both donor lobes (log-rank P  .56).
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bound at the time of transplantation. In addition, 17.9%
were ventilator dependent at the time of transplantation.
Despite the critical condition of many of these recipients,
the overall actuarial survival of 70%, 54%, and 45% at 1, 3,
and 5 years, respectively, is comparable with that of re-
ported double-lung cadaveric transplantation from the
ISHLT Registry (74%, 59%, and 49.5% at 1, 3, and 5 years,
respectively).15 Actuarial survival between adult and pedi-
atric lobar recipients was equivalent. Infection continues to
be the cause of death in the majority of patients. This likely
reflects, once again, the large proportion of patients with
cystic fibrosis in this cohort, but infection was also a com-
mon cause of death in patients undergoing transplantation
for indications other than cystic fibrosis. The incidence of
rejection has not changed since our previous report, with 0.8
episodes per patient. However, more rejection episodes ap-
pear to be synchronous than previously reported because
72% were unilateral and 28% were synchronous in the
present report as opposed to the 98% unilateral episodes in
our previous report. The distribution of grades of rejection
remain similar because 53% of rejection episodes were
classified as grade A2, 35% were classified as grade A1, and








(95% confidence interval) P value
Sex Male 51 25 0.86 (0.42-1.76) .72
Female 72 38
Age Adult 84 45 1.35 (0.63-2.88) .56
Pediatric 39 18
Cystic fibrosis Yes 103 52 0.83 (0.32-2.18) .81
No 20 11
Other indication than cystic fibrosis for
transplantation
Yes 20 11 1.20 (0.46-3.14) .81
No 103 52
Previous transplantation Yes 7 5 2.50 (0.47-13.4) .44
No 116 58
Hospitalized at time of transplantation Yes 83 43 1.08 (0.51-2.29) 1.00
No 40 20
On ventilator at time of transplantation Yes 22 16 3.06 (1.11-8.47) .03
No 101 47
On steroids at time of transplantation Yes 42 19 0.69 (0.33-1.47) .35
No 81 44
Occurrence of 1 rejection episode Yes 67 32 0.74 (0.36-4.79) .47
No 56 31
1 Related donor Yes 102 55 1.90 (0.73-4.98) .23
No 21 8
Figure 4. Actuarial survival on the basis of preoperative intuba-
tion status (log-rank P  .002).
Figure 5. Actuarial survival comparing primary transplantation
versus retransplantation (log-rank P  .13).
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12% were classified as grade A3. Rates of OB have in-
creased from our initial reports with further follow-up but
are still lower than is generally reported in series of cadav-
eric transplantations.16,17
The role of class I and II HLA mismatches on lung
transplantation outcomes remains incompletely understood.
In a study of 3549 cadaveric lung transplantations using
data from the United Network for Organ Sharing/ISHLT
registry that examined the influence of HLA matching on
survival, multivariate logistic regression demonstrated that
the number of mismatches at the HLA-A and HLA-DR loci
predicted 1-year mortality and that the total number of
mismatches predicted 3- and 5-year mortality.18 The results
of our analysis of HLA mismatches failed to show an
association between the recipient and both donor lobes in
terms of survival. The role of HLA mismatches in the
setting of lobar lung transplantation is even more compli-
cated than in the cadaveric setting, given that the number of
potential mismatches is twice that seen with cadaveric trans-
plantation or with living organ transplantations involving
only one donor. On the basis of our results, we would not
recommend restricting potential donors for recipients on the
basis of the number of HLA-A, HLA-B, or HLA-DR mis-
matches between the recipient and the potential donor at the
present time. Perhaps with greater follow-up and numbers
of patients, the potential role of HLA mismatching in lobar
transplantation will become better understood.
A major question regarding lobar lung transplantation
that has been unanswered during the last decade has been
defining when a potential recipient is too ill to justify
placing 2 healthy donors at risk of donor lobectomy. Re-
cipient age, sex, indication for primary transplantation, pre-
hospitalization status, steroid use preoperatively, relation-
ship of the donor to the recipient, and the presence or
absence of rejection episodes postoperatively all did not
appear to influence overall mortality. However, those pa-
tients on ventilators preoperatively, as well as those under-
going retransplantation after either a previous cadaveric or
lobar lung transplantation, had significantly increased odds
ratios for postoperative death. In addition, overall actuarial
survival was markedly lower in intubated versus nonintu-
bated patients. It would thus appear that intubated patients
are at significant risk of poor outcomes, whereas those
undergoing retransplantation are at an increased risk. This
experience is not that dissimilar to the cadaveric experience,
in which intubated patients have higher 1-year mortalities,
and retransplantations have decreased 3- and 5-year surviv-
al.2,15 A similar experience with a smaller number of lobar
transplantations has been reported by the Washington Uni-
versity group.19
A fundamental aspect of living lobar lung transplantation
remains appropriate recipient selection and timing. Al-
though the question of whether a recipient is too well to
justify placing 2 donors at risk remains unanswered by this
report, the question of whether a recipient is too ill to justify
placing 2 donors at risk is now partially answered. On the
basis of the findings in this report, those patients on venti-
lators preoperatively and those patients having undergone a
previous lung transplantation appear to be at high risk for
adverse outcomes with this procedure, and we would rec-
ommend caution in these subgroups of patients because of
the inherent risk to the donors and the poor outcomes in
these recipients. Despite this high-risk patient group, our
results clearly indicate that this alternative procedure has
been life saving in severely ill patients who would either die
or become unsuitable recipients before a cadaveric organ
becomes available. Although cadaveric transplantation is
preferable because of the risk to the donors, living lobar
lung transplantation should continue to be used under prop-
erly selected circumstances.
We thank Earl H. Leonard, MS, for statistical assistance with
this article.
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Discussion
Dr G. Alexander Patterson (St Louis, Mo). Dr Starnes, you and
your colleagues should be congratulated. I think it is a monumental
contribution. We all know that the donor supply is limited, and
there are a number of different options. You can sit tight and do
nothing, or you can do something about it, and that is exactly what
you and your colleagues have done. We have performed a smaller
number of these procedures, and I am well aware of the team that
is required to conduct this kind of work and to achieve the results.
You should be complimented on that as well.
I have a couple of questions. You did a detailed analysis of the
HLA status of donors and recipients side by side. You noticed no
difference in HLA typing among those patients who had a rejec-
tion episode. As a corollary, was there anything peculiar about
those patients who did not have rejection on one side? Was there
something unusual or some identifier in the donors of those uni-
lateral lobes that did not reject? Can we make some prediction for
the future development of BOS? How did you determine that a
patient had unilateral BOS? How many of those patients were
there? Was there something particularly identifiable about those
specific patients?
Also, in this procedure we have to be aware of the donors, and
the article does not comment on the results of donors. Could you
take an opportunity now to share with us some donor information?
How did the donors do? What was their mortality? What was their
morbidity? How do you accomplish a follow-up program in the
donors, particularly for those donors whose recipients experience
a perioperative or late-term death?
Dr Starnes. Thank you, Dr Patterson. Those are extremely nice
comments.
In this study, we only analyzed the relationship of survival to
total HLA antigen mismatches. Development of BOS was hard to
predict, whether unilateral or bilateral. A diagnosis of obliterative
bronchiolitis was made in 16% of the cohort using biopsy or
autopsy end points. An in-depth analysis of the relationship of
outcomes and rejection episodes to HLA class I and II mismatches
is underway, and we should have those results soon.
With regard to the donors, we have had no mortalities in this
group of patients. We have operated on 253 patients for these 128
recipients. We have had some complications, mostly prolonged air
leaks of greater than 5 days in about 8%, and we had some
arrhythmias in about 3%.
As we follow these patients, and we consider them to be
long-term patients, we performed a study to try to understand
whether these patients would donate again, and as you would
predict, 90% of them said they would. The 10% that said they were
not sure or probably would not were in those who donated to
recipients who died in the hospital.
Therefore overall, we think it is a safe operation. We do not
underestimate the risk that we put these donors under each day,
and that is the reason that we would limit this operation to patients
who cannot wait for a cadaveric organ.
Dr Soon J. Park (Minneapolis, Minn). Most of your experi-
ence involves patients with cystic fibrosis. Would you care to
elaborate on the utility of this operation for other patients, such as
those with either pulmonary fibrosis or people with primary pul-
monary hypertension?
Dr Starnes. As you noted in the slide during the presentation,
each of those categories had about 4 or 5 patients in them, and I
know that in the pulmonary hypertensive group, those patients
have done really quite well: we had no operative deaths in those
groups, and in the long term, we have 3 of the 5 patients still alive
at greater than 5 years out. In the pulmonary fibrosis group we had
5 patients; again, immediate operative survival was excellent. We
had 3 late deaths caused by infection.
Dr Fred A. Crawford, Jr (Charleston, SC). Vaughn, I believe
that in your abstract you indicated that the second leading cause of
death was noncompliance, which seemed to be unusually high. Is
this a function of this particular patient population, or is this
something that you have learned to screen for better since then?
Could you comment on that?
Dr Starnes. Yes, this is a particular problem in the pediatric
age group; that is where we had a lot of our pediatric deaths. We
have had, over the last 3 years, 8 deaths caused by teenagers
primarily not taking their medications, and this is a huge problem.
Obviously we are trying to screen for it better, but it continues to
be a problem that keeps coming up in our program, and it is mainly
a pediatric subgroup problem.
Sir Magdi H. Yacoub (London, United Kingdom). Congratu-
lations on your fantastic efforts. It is a bit disappointing that the
incidence of rejection and OB are comparable; everybody ex-
pected them to be better. What do you think the cause for that is,
because these organs have not been subjected to brain death, and
we thought that that would have an effect? And with how many did
you have zero HLA-DR mismatch? And what was your method
of organ preservation? Do you think that has something to do
with it?
Dr Starnes. As it relates to the incidence of OB in adults, I
think the 24% incidence of OB is actually a little lower than we see
in cadaveric transplantation. Was it dramatically lower? No. I
think we still have the problems of viral infections precipitating a
rejection episode, such as CMV, although it is less of a problem
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today than in the past. I think all these do contribute to the
development of OB. Again, noncompliance in the pediatric age
group in particular was a real problem for us that led to rejection
episodes and then finally to OB. Sir Magdi, I really do not have an
answer. I wish I did.
As it relates to preservation of the organ, we used a standard
flush, both antegrade and retrograde, and preservation I do not
think is really an issue because it is a very short ischemia time,
usually less than an hour between harvest and implantation, be-
cause it is usually done in adjacent operating rooms.
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